OmniAb reaches self-sustaining cash flow as its royalty platform gains traction.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Detailed price information for Omniab Inc (OABI-Q) from The Globe and Mail including charting and trades.
EMERYVILLE, Calif., October 06, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration® platform, and introduces the OmniTides™ peptide discovery platform and brand.
EMERYVILLE, Calif., September 14, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA.
On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in […]
EMERYVILLE, Calif., August 26, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management’s participation in the following upcoming investor conferences:
This is the newest page. Registered accounts read further back.